These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 27121864)

  • 1. Proof of concept for inhibiting metastasis: circulating tumor cell-triggered localized release of anticancer agent via a structure-switching aptamer.
    Chen N; Yang X; Wang Q; Jian L; Shi H; Qin S; Wang K; Huang J; Liu W
    Chem Commun (Camb); 2016 May; 52(41):6789-92. PubMed ID: 27121864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer/Graphene Quantum Dots Nanocomposite Capped Fluorescent Mesoporous Silica Nanoparticles for Intracellular Drug Delivery and Real-Time Monitoring of Drug Release.
    Zheng FF; Zhang PH; Xi Y; Chen JJ; Li LL; Zhu JJ
    Anal Chem; 2015 Dec; 87(23):11739-45. PubMed ID: 26524192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
    Joshi M; Choi JS; Park JW; Doh KO
    J Microbiol Biotechnol; 2019 Nov; 29(11):1799-1805. PubMed ID: 31546295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photo-controlled delivery of a potent analogue of doxorubicin.
    Dupart PS; Mitra K; Lyons CE; Hartman MCT
    Chem Commun (Camb); 2019 May; 55(39):5607-5610. PubMed ID: 31021353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epithelial cell adhesion molecule aptamer conjugated PEG-PLGA nanopolymersomes for targeted delivery of doxorubicin to human breast adenocarcinoma cell line in vitro.
    Alibolandi M; Ramezani M; Sadeghi F; Abnous K; Hadizadeh F
    Int J Pharm; 2015 Feb; 479(1):241-51. PubMed ID: 25529433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamer-drug conjugation for targeted tumor cell therapy.
    Donovan MJ; Meng L; Chen T; Zhang Y; Sefah K; Tan W
    Methods Mol Biol; 2011; 764():141-52. PubMed ID: 21748638
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release of photoactivatable drugs from plasmonic nanoparticles for targeted cancer therapy.
    Luo YL; Shiao YS; Huang YF
    ACS Nano; 2011 Oct; 5(10):7796-804. PubMed ID: 21942498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer CaCO3 nanostructures: a facile, pH-responsive, specific platform for targeted anticancer theranostics.
    Zhou C; Chen T; Wu C; Zhu G; Qiu L; Cui C; Hou W; Tan W
    Chem Asian J; 2015 Jan; 10(1):166-71. PubMed ID: 25377905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microenvironmental Control of MUC1 Aptamer-Guided Acid-Labile Nanoconjugate within Injectable Microporous Hydrogels.
    Xu C; Han X; Jiang Y; Yuan S; Wu Z; Wu Z; Qi X
    Bioconjug Chem; 2017 Oct; 28(10):2530-2537. PubMed ID: 28949511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biodegradable ZnO@polymer core-shell nanocarriers: pH-triggered release of doxorubicin in vitro.
    Zhang ZY; Xu YD; Ma YY; Qiu LL; Wang Y; Kong JL; Xiong HM
    Angew Chem Int Ed Engl; 2013 Apr; 52(15):4127-31. PubMed ID: 23463695
    [No Abstract]   [Full Text] [Related]  

  • 11. Boron Nitride Nanoparticles with a Petal-Like Surface as Anticancer Drug-Delivery Systems.
    Sukhorukova IV; Zhitnyak IY; Kovalskii AM; Matveev AT; Lebedev OI; Li X; Gloushankova NA; Golberg D; Shtansky DV
    ACS Appl Mater Interfaces; 2015 Aug; 7(31):17217-25. PubMed ID: 26192448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An in vitro assessment of novel chitosan/bimetallic PtAu nanocomposites as delivery vehicles for doxorubicin.
    Maney V; Singh M
    Nanomedicine (Lond); 2017 Nov; 12(21):2625-2640. PubMed ID: 28965478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer nano-prodrugs with drug release triggered by intracellular dissolution and hydrogen peroxide response.
    Shibata A; Koseki Y; Tanita K; Kitajima S; Oka K; Maruoka K; Suzuki R; Thi Ngoc Dao A; Kasai H
    Chem Commun (Camb); 2024 Jun; 60(50):6427-6430. PubMed ID: 38829169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Stimuli-Responsive Controlled Release Nanocarrier for Multidrug Resistance Cancer Therapy.
    Jiao X; Wang Z; Wang F; Wen Y
    Chemphyschem; 2019 Dec; 20(24):3271-3275. PubMed ID: 31654459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An NIR-triggered and thermally responsive drug delivery platform through DNA/copper sulfide gates.
    Zhang L; Li Y; Jin Z; Yu JC; Chan KM
    Nanoscale; 2015 Aug; 7(29):12614-24. PubMed ID: 26147639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of MnSOD promotes survival of circulating breast cancer cells and increases their resistance to doxorubicin.
    Fu A; Ma S; Wei N; Tan BX; Tan EY; Luo KQ
    Oncotarget; 2016 Aug; 7(31):50239-50257. PubMed ID: 27384484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboxylated hydroxyethyl starch: a novel polysaccharide for the delivery of doxorubicin.
    Paleos CM; Sideratou Z; Theodossiou TA; Tsiourvas D
    Chem Biol Drug Des; 2015 May; 85(5):653-8. PubMed ID: 25303215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polyvalent aptamer system for targeted drug delivery.
    Zhang Z; Ali MM; Eckert MA; Kang DK; Chen YY; Sender LS; Fruman DA; Zhao W
    Biomaterials; 2013 Dec; 34(37):9728-35. PubMed ID: 24044994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aptamer-based liposomes improve specific drug loading and release.
    Plourde K; Derbali RM; Desrosiers A; Dubath C; Vallée-Bélisle A; Leblond J
    J Control Release; 2017 Apr; 251():82-91. PubMed ID: 28238787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of molecular structure on the anticancer drug release rate from prodrug nanoparticles.
    Ikuta Y; Koseki Y; Onodera T; Oikawa H; Kasai H
    Chem Commun (Camb); 2015 Aug; 51(64):12835-8. PubMed ID: 26165183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.